Illumination Acquisition Corp. I (ILLUU)

November 2025. Mr. Lipman is the head of capital markets at Lucid Capital Markets, LLC. He has more than 20 years of investment banking experience advising growth companies in the healthcare, industrial and technology sectors. Mr. Lipman has completed over 250 equity, convertible and debt offerings and advisory assignments for growth companies. Before joining Lucid, Mr. Lipman was a partner and managing director of investment banking at Craig-Hallum, managing director at Hudson Securities, and managing director at Carter Securities, a firm he founded that specialized in raising equity, equity-linked and debt capital for growth companies. He also has several years of SPAC experience as either the COO or the co-CEO of SPACs under the Roth CH Acquisition name.their chairman of the board, is a co-founder and the CEO of Lucid. From December 2011 until joining Lucid, Mr. Rosenberg was co-president and CEO of Ladenburg Thalmann & Co Inc. Mr. Rosenberg remained with Ladenburg through the successful sale of Ladenburg Thalmann Financial Services for $1.3 billion to Osaic Wealth (f/k/a Advisor Group) a portfolio company of Reverence Capital Partners, a leading financial services-focused private equity firm. Before joining Ladenburg Thalmann in 2006, Mr. Rosenberg was co-founder and CEO of BroadWall Capital, LLC, an independent provider of equity research, investment banking, institutional sales and trading and wealth management. He joined Ladenburg Thalmann after successfully selling assets of BroadWall Capital in 2006 to Ladenburg Thalmann & Co Inc. Mr. Rosenberg brings over 25 years of investment banking experience focused on growth companies. Since 2006, Mr. Rosenberg has managed over 750 public offerings, including but not limited to IPOs and follow-on offerings, raising in excess of $100 billion for small and mid-cap companies, as well as advising on many merger and acquisition transactions. Mr. Rosenberg also served as the chairman and co-CEO of Ignyte Acquisition Corp. from August 2020 until its merger with Peak Bio Co., Ltd., n/k/a Akari Therapeutics, Plc (Nasdaq: AKTX) in November 2022.

Industry
Blank Checks

CEO	CFO
-

Employees	Founded
0	2025

Address: 570 Lexington Ave, 40th Floor New York, Ny 10022

Telephone: (646) 348-9369

Web page:

First Trade Date	2/27/2026
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the ILLUU share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Underwriters
BTIG
CO-Managers